Piramal Critical Care (PCC), a division of Piramal Pharma Ltd., has announced the US launch of Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio.

Peter DeYoung, Chief Executive Officer, Piramal Global Pharma commented, “We are excited to launch Chlorpromazine Hydrochloride for Injection, USP, which joins our growing US portfolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”

The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 ml vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market.

In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products.